Vaccines Europe pipeline review

Dashboard

Vaccines Europe conducted a pipeline review of its 15 member companies, including information up to August 2023.

The review shows a promising vaccines pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the ageing of the population, climate change and zoonotic infections, through leveraging a broad array of technology platforms.

DOWNLOAD PIPELINE REVIEW

Overview data

103

vaccine candidates in Vaccines Europe members’ pipeline, of which 99 are prophylactic vaccines and 4 are therapeutic vaccines.

42%

of vaccine candidates aim to address disease areas for which no vaccine has been registered yet.

58%

of the vaccine candidates aim to further develop existing vaccines or find a new approach to address a disease.

38

of the vaccine candidates are for routine immunisation.

5

vaccine candidates aim to treat different types of cancer.

Almost 15%

of vaccine candidates are targeting antibiotic resistant pathogens.

Over 80%

of vaccine candidates are testing in adults and older adults.

12

different technology platforms are being used by Vaccines Europe members in their pipelines.

Over 60%

of vaccine candidates aim to tackle respiratory-transmitted diseases.

15%

of vaccine candidates are for travel.

60%

of vaccine candidates are focused on preventing zoonotic diseases.

Explore the latest vaccines in development

SEARCH BY

all_diseases_area
All Disease Areas
technology_platform
Technology Platforms
development_phases
Development Phases
trial_population
Trial Population

CHOOSE THE DISEASE OR PATHOGEN

salmonella Salmonella
norovirus Norovirus
hmpv Human metapneumovirus and RSV (hMPV/RSV)
hepatitis-b Hepatitis B
gonorrhea Gonorrhoea
hpv Human papillomavirus (HPV)
Chikungunya Chikungunya Virus
covid-19 Coronaviruses
clostridioides Clostridioides difficile infection (CDI)
cytomegalovirus Cytomegalovirus
dengue-fever Dengue fever
epstein-barr-virus Epstein-Barr virus (EBV) infection
glioblastoma Glioblastoma (CMV-positive)
streptococcus Group B Streptococcus Infection
herpes-simplex Herpes simplex virus
hiv Human immunodeficiency virus (HIV)
influenza Influenza
klebsiella-pneumoniae Klebsiella pneumoniae
e-coli Invasive Escherichia Coli Disease
lyme-disease-image Lyme disease (Borreliosis)
malaria Malaria
meningococcal-disease Meningococcal disease
nipah-virus Nipah virus (NiV)
pneumococcal-disease Pneumococcal disease
rabies Rabies
rsv Respiratory Syncytial Virus (RSV)​
shigellosis Shigellosis
varicella Varicella
zika-image Zika
yellow-fever-e1689505535523-1 Yellow fever

CHOOSE A TECHNOLOGY PLATFORM

Generalised Modules for Membrane Antigens
Salmonella Gonorrhoea Shigellosis
Glycoconjugate vaccine
Salmonella Group B Streptococcus Infection Klebsiella pneumoniae Invasive Escherichia Coli Disease Meningococcal disease Pneumococcal disease
Live-attenuated virus​
Chikungunya Virus Dengue fever Respiratory Syncytial Virus (RSV)​ Varicella Yellow fever
Monoclonal antibody
Coronaviruses
Multiple platforms
Hepatitis B Meningococcal disease
Protein nanoparticles
Coronaviruses Influenza Malaria Respiratory Syncytial Virus (RSV)​
Protein subunit​
Human papillomavirus (HPV) Coronaviruses Clostridioides difficile infection (CDI) Cytomegalovirus Herpes simplex virus Lyme disease (Borreliosis) Malaria Meningococcal disease Pneumococcal disease Respiratory Syncytial Virus (RSV)​
RNA
Norovirus Human metapneumovirus and RSV (hMPV/RSV) Coronaviruses Cytomegalovirus Epstein-Barr virus (EBV) infection Herpes simplex virus Human immunodeficiency virus (HIV) Influenza Lyme disease (Borreliosis) Nipah virus (NiV) Rabies Respiratory Syncytial Virus (RSV)​ Varicella Zika
Toxoid vaccine
Clostridioides difficile infection (CDI)
Viral vector
Coronaviruses Respiratory Syncytial Virus (RSV)​
Virus-like particle​
Hepatitis B Coronaviruses Cytomegalovirus Glioblastoma (CMV-positive)
Whole-inactivated virus​
Influenza Rabies Zika

CHOOSE A DEVELOPMENT PHASE

phase-I

Phase I

Salmonella Norovirus Human metapneumovirus and RSV (hMPV/RSV) Coronaviruses Clostridioides difficile infection (CDI) Cytomegalovirus Epstein-Barr virus (EBV) infection Herpes simplex virus Human immunodeficiency virus (HIV) Influenza Klebsiella pneumoniae Lyme disease (Borreliosis) Nipah virus (NiV) Rabies Respiratory Syncytial Virus (RSV)​ Varicella Zika
phase-II

Phase II

Hepatitis B Gonorrhoea Human papillomavirus (HPV) Coronaviruses Clostridioides difficile infection (CDI) Dengue fever Glioblastoma (CMV-positive) Group B Streptococcus Infection Herpes simplex virus Influenza Malaria Meningococcal disease Pneumococcal disease Respiratory Syncytial Virus (RSV)​ Shigellosis Varicella Zika Yellow fever
phase-III

Phase III

Chikungunya Virus Coronaviruses Clostridioides difficile infection (CDI) Cytomegalovirus Influenza Invasive Escherichia Coli Disease Lyme disease (Borreliosis) Malaria Meningococcal disease Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)​
under-review

Under Regulatory Review

Coronaviruses Influenza Meningococcal disease Respiratory Syncytial Virus (RSV)​

CHOOSE A TRIAL POPULATION

adults

Adults

Salmonella Norovirus Hepatitis B Gonorrhoea Human papillomavirus (HPV) Chikungunya Virus Coronaviruses Clostridioides difficile infection (CDI) Cytomegalovirus Dengue fever Epstein-Barr virus (EBV) infection Glioblastoma (CMV-positive) Group B Streptococcus Infection Herpes simplex virus Human immunodeficiency virus (HIV) Influenza Klebsiella pneumoniae Lyme disease (Borreliosis) Malaria Meningococcal disease Nipah virus (NiV) Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)​ Shigellosis Varicella Zika Yellow fever

N/A

Coronaviruses Clostridioides difficile infection (CDI) Respiratory Syncytial Virus (RSV)​ Varicella
older-adults

Older Adults

Coronaviruses Clostridioides difficile infection (CDI) Dengue fever Glioblastoma (CMV-positive) Influenza Klebsiella pneumoniae Invasive Escherichia Coli Disease Meningococcal disease Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)​ Varicella Yellow fever
paediatric

Paediatric

Human metapneumovirus and RSV (hMPV/RSV) Gonorrhoea Human papillomavirus (HPV) Coronaviruses Dengue fever Influenza Lyme disease (Borreliosis) Malaria Meningococcal disease Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)​ Varicella Zika Yellow fever

OR SEARCH BY REPORT SECTIONS

ico-antimicrobal
Antimicrobal resistance

CHOOSE THE DISEASE OR PATHOGEN

salmonella Salmonella
clostridioides Clostridioides difficile infection (CDI)
klebsiella-pneumoniae Klebsiella pneumoniae
e-coli Invasive Escherichia Coli Disease
pneumococcal-disease Pneumococcal disease
shigellosis Shigellosis
ico-climate-change
Climate change

CHOOSE THE DISEASE OR PATHOGEN

Chikungunya Chikungunya Virus
dengue-fever Dengue fever
malaria Malaria
zika-image Zika
ico-infection-associated 60×60
Infection-associated cancer vaccines

CHOOSE THE DISEASE OR PATHOGEN

hpv Human papillomavirus (HPV)
epstein-barr-virus Epstein-Barr virus (EBV) infection
glioblastoma Glioblastoma (CMV-positive)
ico-routine-vaccine
Routine vaccines across the lifespan

CHOOSE THE DISEASE OR PATHOGEN

streptococcus Group B Streptococcus Infection
influenza Influenza
meningococcal-disease Meningococcal disease
pneumococcal-disease Pneumococcal disease
rsv Respiratory Syncytial Virus (RSV)​
varicella Varicella
ico-therapeutic
Therapeutic vaccines

CHOOSE THE DISEASE OR PATHOGEN

hepatitis-b Hepatitis B
glioblastoma Glioblastoma (CMV-positive)
herpes-simplex Herpes simplex virus
ico-travel-vaccines-1
Travel vaccines

CHOOSE THE DISEASE OR PATHOGEN

salmonella Salmonella
Chikungunya Chikungunya Virus
dengue-fever Dengue fever
meningococcal-disease Meningococcal disease
rabies Rabies
yellow-fever-e1689505535523-1 Yellow fever
ico-pandemic
Zoonoses and pandemic preparedness

CHOOSE THE DISEASE OR PATHOGEN

salmonella Salmonella
Chikungunya Chikungunya Virus
covid-19 Coronaviruses
dengue-fever Dengue fever
influenza Influenza
lyme-disease-image Lyme disease (Borreliosis)
malaria Malaria
nipah-virus Nipah virus (NiV)
rabies Rabies

Charts

By the end of August 2023, there were 103 vaccine candidates in the Vaccines Europe members’ pipeline. Most of these target infectious diseases caused by viruses. The majority of vaccine candidates target the adult population, especially for those at higher risk for serious disease infection. Meanwhile, almost half of the vaccine candidates target diseases for which there are no registered vaccines yet.

How can Europe take full advantage of this promising vaccines pipeline?

1
Ensure sustainable immunisation financing in EU Member States
2
Enhance vaccine market access pathways in Europe
3
Embed adult vaccination in national immunisation programmes to improve country readiness

EU Vaccines Pipeline Review

DOWNLOAD PIPELINE REVIEW